联系方式

实验室位置:

武汉大学基础医学院3号楼5楼

Email:

kegong@whu.edu.cn

龚克 特聘研究员

职称职务:特聘研究员

学科专业:免疫学

研究方向:肿瘤信号通路与靶向免疫治疗,数据库和精准治疗

实验室位置:武汉大学基础医学院3号楼5楼

Email: kegong@whu.edu.cn

学习经历

2003-2007 武汉大学生命科学学院,学士

2008-2014 武汉大学生命科学学院,细胞生物学,博士

主要工作经历与任职

2014-2015 美国埃默里大学 博士后

2015-2019 美国西南医学中心 博士后

2019-2021 美国西南医学中心 讲师

2021-至今  武汉大学基础医学院免疫系 特聘研究员

目前主要科学研究领域和兴趣

以表皮生长因子EGFR为代表的受体酪氨酸激酶(RTK)癌基因信号异常与肿瘤发生发展及治疗抵抗高度相关。当前肿瘤精准治疗正面临两大挑战:(1)靶向治疗药物虽然对癌基因异常肿瘤早期效果显著,但最终仍不可避免发生继发耐药,且野生型原初耐药;(2)免疫检查点药物虽能持续抑制部分肿瘤,但对如RTK异常肿瘤疗效欠佳。前期在美国的课题组研究探索了抗病毒天然免疫信号通路参与肿瘤靶向耐药的分子机制,发现了非小细胞肺癌中,靶向EGFR的小分子抑制剂药物能够拉拢天然免疫通路释放I型干扰素,抵抗靶向治疗,影响PDL1相关的免疫治疗(Nature Cancer,2020),并诱导释放肿瘤坏死因子TNF-α,在非小细胞肺癌及脑神经胶质瘤中介导炎症反应导致适应性耐药(J CIin Invest. 2018,Nat Neurosci. 2017,Neuro Oncol. 2019,Neoplasia 2021)。

课题组的研究方向包括

免疫应答与炎症反应参与肿瘤靶向与免疫治疗抵抗的分子机制;2. 基于临床医学问题,对作用于肿瘤发生发展及治疗耐药,并影响病人预后转归的新基因靶点、新信号通路,开展数据库筛查、实验模型验证、及分子机制探索等基础医学和生命科学研究;3. 针对新治疗靶点和耐药机制的临床治疗方案转化。

欢迎对肿瘤治疗方向感兴趣的学生、助研、博后加入团队!

教学情况

本科生课程《基础医学导论》、研究生课程《免疫学前沿进展》

获批资助项目

武汉大学人才引进项目

近期代表性论文

1. Ke Gong, Gao Guo, Nishah Panchani, Matthew E. Bender, David E. Gerber, John D. Minna, Farjana Fattah, Boning Gao, Michael Peyton, Kemp Kernstine, Bipasha Mukherjee, Sandeep Burma, Cheng-Ming Chiang, Shanrong Zhang, Adwait Amod Sathe, Chao Xing, Kathryn H. Dao, Dawen Zhao, Esra A. Akbay, and Amyn A. Habib* EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nature Cancer. 2020 1(4): 394–409. (Highlighted by Nature Cancer,Cancer Discovery and Nature Reviews Cancer)

2. Gong K, Guo G, E Gerber D, Gao B, Peyton M, Huang C, D Minna J, J Hatanpaa K, Kernstine K, Cai L, Xie Y, Zhu H, Fattah F, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, A Papadimitrakopoulou V, Olivas V, G Bivona T, Zhao D, A Habib A*. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Journal of Clinical Investigation. 2018 128(6):2500-2518 Co-first author

3. Ke Gong*, Gao Guo, Nicole Beckley, Yue Zhang, Xiaoyao Yang, Mishu Sharma, Amyn A.Habib* Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment. Neoplasia. 2021 23(2):189-196

4. Zhi-Hao Wang, Ke Gong, Xia Liu, Zhentao Zhang, Xiaoou Sun, Zheng Wei, Shan Yu, Fredric P Manfredsson, Ivette Sandoval, Peter Johnson, Jianping Jia, Jian-Zhi Wang, and Keqiang Ye* C/EBPβ regulates Delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer’s Disease. Nature Communications. 2018 9(1):1784 Co-first author

5. Ke Gong, Zhenxing Zhang, Yicheng Chen, Hong-Bing Shu, Wenhua Li* Extracellular signal-regulated kinase, receptor interacting protein, and reactive oxygen species regulate shikonin-induced autophagy in human hepatocellular carcinoma. European Journal of Pharmacology. 2014 738:142-52

6. Ke Gong, Chao Chen, Yao Zhan, Yan Chen, Zebo Huang, Wenhua Li*. Autophagy-related gene 7 (Atg7) and reactive oxygen species (ROS)/extracellular-signal-regulated kinase (ERK) regulate tetrandrine-inducedautophagy in human hepatocellular carcinoma. Journal of Biological Chemistry.2012, 287:35576-88 Co-first author

7. Ke Gong, Jia Xie, Hong Yi, Wenhua Li*. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1-arrest, ROS-dependent apoptosis and differentiation in human leukemia cells. Biochemical Journal. 2012, 443:735-46

8. Ke Gong, Wenhua Li* Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma Free Radical Biology and Medicine. 2011, 51:2259-71.


版权所有:武汉大学基础医学院 ALL RIGHTS RESERVED 2021